Kintara Therapeutics, Inc. (NASDAQ:KTRA) Sees Large Increase in Short Interest

Kintara Therapeutics, Inc. (NASDAQ:KTRAGet Free Report) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 4,740,000 shares, an increase of 319.5% from the May 15th total of 1,130,000 shares. Based on an average daily trading volume, of 16,470,000 shares, the short-interest ratio is currently 0.3 days.

Kintara Therapeutics Stock Up 0.9 %

NASDAQ KTRA traded up $0.00 on Friday, hitting $0.19. 985,169 shares of the company were exchanged, compared to its average volume of 13,617,569. The firm has a 50 day moving average of $0.17 and a two-hundred day moving average of $0.15. Kintara Therapeutics has a 1-year low of $0.08 and a 1-year high of $5.60.

Kintara Therapeutics (NASDAQ:KTRAGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter.

About Kintara Therapeutics

(Get Free Report)

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.

See Also

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with's FREE daily email newsletter.